NIH disease funding levels and burden of disease

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Gillum, Leslie A ^a   Gouveia, Christopher ^a   Dorsey, E Ray ^b   Pletcher, Mark ^a   Mathers, Colin D ^c   McCulloch, Charles E ^a   Johnston, S Claiborne ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACCOUNTING; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RESEARCH; CONTROLLED STUDY; COST OF ILLNESS; DEPRESSION; DIABETES MELLITUS; FUNDING; HEALTH CARE FINANCING; HEALTH CARE SURVEY; HEALTH SERVICES RESEARCH; HUMAN; INCIDENCE; INJURY; MAJOR CLINICAL STUDY; MORTALITY; NATIONAL HEALTH ORGANIZATION; PERINATAL CARE; PREDICTION; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STANDARDIZATION; CLASSIFICATION; CROSS-SECTIONAL STUDY; ECONOMICS; EPIDEMIOLOGY; EVALUATION; FEMALE; FINANCIAL MANAGEMENT; GENERAL ASPECTS OF DISEASE; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; RESEARCH; UNITED STATES;

COST OF ILLNESS; CROSS-SECTIONAL STUDIES; DISEASE; EPIDEMIOLOGY; FEMALE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; NATIONAL INSTITUTES OF HEALTH (U.S.); QUALITY-ADJUSTED LIFE YEARS; RESEARCH; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 79952087469     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016837     Document Type: Article

References (52)

1. Moses H 3rd, Dorsey ER, Matheson DH, Thier SO, (2005) Financial anatomy of biomedical research. JAMA 294: 1333-1342.
2. European Science Foundation (2007) Present status and future strategy for medical research in Europe. European Science Foundation, www.esf.org, accessed October 28, 2008.
3. NIH Office of Budget NIH appropriations history by institute and center. Office of Budget, Office of the Director, National Institutes of Health, Department of Health and Human Services, http://officeofbudget.od.nih.gov/UI/AppropriationsHistoryByIC.htm, accessed May 5, 2008.
4. Institute of Medicine (1998) Scientific opportunities and public needs: Improving priority setting and public input at the NIH. National Institutes of Health Priority Setting Committee, Institute of Medicine. National Academy Press, http://www.nap.edu, accessed March 1, 2008.
5. Gross CP, Anderson GF, Powe NR, (1999) The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med 340: 1881-1887.
6. Morrow RH, Bryant JH, (1995) Health policy approaches to measuring and valuing human life: conceptual and ethical issues. Am J Public Health 85: 1356-1360.
7. Murray CJL, (1996) Rethinking DALYs. In: Murray CJL, Lopez AD, editors. The global burden of disease Cambridge Harvard School of Public Health on behalf of the World Health Organization and the World Bank pp. 1-98.
8. National Institutes of Health Reform Act of 2006.
9. Nahin RL, (2005) Identifying and pursuing research priorities at the National Center for Complementary and Alternative Medicine. FASEB J 19: 1209-1215.
10. World Health Organization (2006) Global burden of disease: Cause Category and ICD-9 Codes.: World Health Organization. The World Bank Group, http://www.dcp2.org/pubs/GBD/3/Table/3.A2, accessed February 8, 2008.
11. National Institutes of Health (2008) Estimates of funding for various diseases, conditions, research areas. National Institutes of Health, Department of Health and Human Services, http://www.nih.gov/news/fundingresearchareas.htm, accessed May 16, 2007.
12. Lopez AD, (2005) The evolution of the Global Burden of Disease framework for disease, injury and risk factor quantification: developing the evidence base for national, regional and global public health action. Global Health 1: 5.
13. Lopez AD, Mathers CD, Ezzati M, Murrary CJL, Jamison DT, (2006) Global burden of disease and risk factors New York Oxford University Press.
14. World Health Organization (2008) The global burden of disease: 2004 update Geneva, Switzerland WHO Press.
15. Murray CJ, Lopez AD, (1997) Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349: 1436-1442.
16. Murray CJL, Lopez AD, Harvard School of Public Health, World Health Organization, World Bank (1996) The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020 Cambridge, MA Harvard University Press pp. xxxii, 990.
17. Healthcare Cost and Utilization Project (2008) HCUPnet: National statistics on hospital stays. Agency for Healthcare Research and Quality, http://hcupnet.ahrq.gov/, accessed December 15, 2007.
18. National Center for Health Statistics (2008) Ambulatory health care data: National Ambulatory Medical Care Survey (NAMCS). Centers for Disease Control and Prevention, US Department of Health and Human Services, http://www.cdc.gov/nchs/about/major/ahcd/ahcd1.htm, accessed November 29, 2007.
19. Agency for Healthcare Research and Quality (2005) Introduction to the HCUP Nationwide Inpatient Sample (NIS), http://www.hcupus.ahrq.gov/db/nation/nis/NIS_Introduction_2005.jsp Introduction 2005.jsp, accessed May 1, 2008.
20. National Center for Health Statistics (2008) Ambulatory health care data: National Hospital Ambulatory Medical Care Survey (NHAMCS). Centers for Disease Control and Prevention, US Department of Health and Human Services, http://www.cdc.gov/nchs/about/major/ahcd/ahcd1.htm, accessed November 29, 2007.
21. LexisNexis News (2008) ed: Reed Elsevier Inc, http://www.lexisnexis.com, accessed June 5, 2008.
22. Vanderbilt Univeristy (2008) Vanderbilt Television News Archive. http://tvnews.vanderbilt.edu/, accessed July 15, 2008.
23. Charity Navigator (2006) Your guide to intelligent giving, www.charitynavigator.com, accessed August 14, 2008.
24. United States Patent and Trademark Office (2008) USPTO patent full-text and image database: patent applications. United States Patent and Trademark Office, http://patft.uspto.gov/, accessed July 11, 2008.
25. National Center for Biotechnology Information (2008) PubMed Central. US National Library of Medicine, http://www.ncbi.nlm.nih.gov/sites/entrez/, accessed August 7, 2008.
26. Saha S, Saint S, Christakis DA, (2003) Impact factor: a valid measure of journal quality? J Med Libr Assoc 91: 42-46.
27. Bradu D, Mundlak Y, (1970) Estimation of lognormal linear models. Journal of the American Statistical Association 65: 198-211.
28. Goldberger AS, (1968) The interpretation and estimation of Cobb-Douglas functions. Econometrica 36: 464-472.
29. Friedman MS, (2008) The Inflation Calculator. S. Morgan Friedman, http://www.westegg.com/inflation/, accessed November 11, 2008.
30. Mathers CD, Loncar D, (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: e442.
31. Lichtenberg FR, American Enterprise Institute for Public Policy Research (1999) The allocation of public funds for biomedical R&D Washington, D.C. AEI Press pp. v, 41.
32. National Institutes of Health (1993) Cost-savings resulting from NIH research support. 2nd ed. NIH Publication 93-3109. Rockville, MD.
33. Food and Drug Administration (2008) Clinical studies of safety and effectiveness of orphan products. Research project grant (RO1). RFA-FD08-001. U.S. Food and Drug Administration, U.S. Department of Health and Human Services, http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-08-001.html, accessed November 1, 2008.
34. Food and Drug Administration (2008) Office of Orphan Products Development. U.S. Food and Drug Administration, http://www.fda.gov/orphan/, accessed November 1, 2008.
35. NIH Office of Rare Diseases (2008) National Institutes of Health, Department of Health and Human Services, http://rarediseases.info.nih.gov/, accessed November 1, 2008.
36. Ad Hoc Committee on Health Research Relating to Future Intervention Options (1996) Investing in health research and development Geneva World Health Organization.
37. Katz DA, Muehlenbruch DR, Brown RL, Fiore MC, Baker TB, (2004) Effectiveness of implementing the agency for healthcare research and quality smoking cessation clinical practice guideline: a randomized, controlled trial. J Natl Cancer Inst 96: 594-603.
38. National Institute of Allergy and Infectious Diseases (2006) Fiscal Year 2007 Budget Justification. http://www3.niaid.nih.gov/about/overview/budget/PDF/fy07 justification.pdf, accessed Nov. 1, 2008.
39. Gitterman DP, Hay WW Jr, (2008) That sinking feeling, again? The state of National Institutes of Health pediatric research funding, fiscal year 1992-2010. Pediatr Res 64: 462-469.
40. NIH Almanac (2008) National Institute of Diabetes and Digestive and Kidney Illnesses - Mission and history. http://www.nih.gov/about/almanac/organization/NIDDK.htm, accessed Jan. 12, 2009.
41. National Institutes of Health (2009) NIH Institutes, Centers and Offices. National Institutes of Health, Department of Health and Human Services, http://www.nih.gov/icd/index.html, accessed April 27, 2009.
42. NIH Office of Budget (2009) NIH Common Fund/Roadmap. Office of Budget, Office of the Director, National Institutes of Health, Department of Health and Human Services, http://officeofbudget.od.nih.gov/ui/2008/Final%20Roadmap.pdf, accessed April 27, 2009.
43. National Institutes of Health (2008) NIH career award funding 1998-2007. Office of Research Information Systems, National Institutes of Health, Department of Health and Human Services, http://report.nih.gov/NIH_Investment/PDF_sectionwise/NIH_Extramural_DataBook_PDF/NEDB%20CAREER%20DEVELOPMENT.pdf, accessed April 27, 2009.
44. National Institutes of Health (2007) NIH director selects Dr. Alan M. Krensky as NIH deputy director for the Office of Portfolio Analysis and Strategic Initiatives (OPASI) National Institutes of Health, Department of Health and Human Services, http://www.nih.gov/news/pr/jan2007/opasi-25.htm, accessed May 5, 2009.
45. National Institute of Neurological Disorders and Stroke (2009) Grant opportunities in comparative effectiveness research. National Institutes of Health, Department of Health and Human Services, http://www.ninds.nih.gov/recovery/arra-funding/go-cer.htm, accessed May 5, 2009.
46. Varmus H, (1999) Evaluating the burden of disease and spending the research dollars of the National Institutes of Health. N Engl J Med 340: 1914-1915.
47. National Science Foundation (2007) Federal funds for research and development: Fiscal years 2004-06. NSF 07-323. John E. Jankowski, project officer.: National Science Foundation, Division of Science Resources Statistics, http://www.nsf.gov/statistics/nsf07323/pdf/tab3.pdf, accessed May 1, 2008.
48. Department of Veterans Affairs (2006) Fiscal Year 2006 performance and accountability report: consolidated financial statements Washington D.C. Department of Veterans Affairs, Office of Management pp. 285-290.
49. Burns L, ArchstoneConsulting (2009) The biopharmaceutical sector's impact on the U.S. economy: analysis at the national, state, and local levels Stamford, CT Archstone Consulting.
50. Dorsey ER, Vitticore P, De Roulet J, Thompson JP, Carrasco M, et al. (2006) Financial anatomy of neuroscience research. Ann Neurol 60: 652-659.
51. Mathers CD, Salomon JA, Ezzati M, Begg S, Lopez AD, (2006) Sensitivity and uncertainty analyses for burden of disease and risk factor estimates. Global burden of disease and risk factors New York Oxford University Press pp. 399-426.
52. Johnston SC, Rootenberg JD, Katrak S, Smith WS, Elkins JS, (2006) Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet 367: 1319-1327.